AU2010217453B2 - Antibodies specifically directed to the soluble form of CTLA-4 - Google Patents

Antibodies specifically directed to the soluble form of CTLA-4 Download PDF

Info

Publication number
AU2010217453B2
AU2010217453B2 AU2010217453A AU2010217453A AU2010217453B2 AU 2010217453 B2 AU2010217453 B2 AU 2010217453B2 AU 2010217453 A AU2010217453 A AU 2010217453A AU 2010217453 A AU2010217453 A AU 2010217453A AU 2010217453 B2 AU2010217453 B2 AU 2010217453B2
Authority
AU
Australia
Prior art keywords
antibody
antibody molecule
domain
sctla
ctla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010217453A
Other languages
English (en)
Other versions
AU2010217453A1 (en
Inventor
Robert Norman Barker
Lekh Nath Dahal
Frank James Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
Original Assignee
University of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Aberdeen filed Critical University of Aberdeen
Publication of AU2010217453A1 publication Critical patent/AU2010217453A1/en
Application granted granted Critical
Publication of AU2010217453B2 publication Critical patent/AU2010217453B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2010217453A 2009-02-26 2010-02-26 Antibodies specifically directed to the soluble form of CTLA-4 Ceased AU2010217453B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0903325.9A GB0903325D0 (en) 2009-02-26 2009-02-26 Antibody molecules
GB0903325.9 2009-02-26
PCT/GB2010/000351 WO2010097597A1 (en) 2009-02-26 2010-02-26 Antibodies specifically directed to the soluble form of ctla-4

Publications (2)

Publication Number Publication Date
AU2010217453A1 AU2010217453A1 (en) 2011-10-20
AU2010217453B2 true AU2010217453B2 (en) 2017-05-25

Family

ID=40565800

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010217453A Ceased AU2010217453B2 (en) 2009-02-26 2010-02-26 Antibodies specifically directed to the soluble form of CTLA-4

Country Status (9)

Country Link
US (1) US8697845B2 (enExample)
EP (1) EP2401035B1 (enExample)
JP (1) JP5864266B2 (enExample)
CN (1) CN102421482B (enExample)
AU (1) AU2010217453B2 (enExample)
CA (1) CA2772648A1 (enExample)
ES (1) ES2662652T3 (enExample)
GB (1) GB0903325D0 (enExample)
WO (1) WO2010097597A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6074435B2 (ja) * 2011-10-26 2017-02-01 ナショナル キャンサー センター 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物
KR20160004299A (ko) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
AU2016370648B2 (en) * 2015-12-15 2023-03-09 OncoC4, Inc. Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) * 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
AU2017370731B2 (en) 2016-12-08 2022-06-02 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
SG11201907867TA (en) * 2017-02-28 2019-09-27 Bristol Myers Squibb Co Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
SG11202005692WA (en) * 2017-12-20 2020-07-29 Harbour Biomed Shanghai Co Ltd Antibodies binding ctla-4 and uses thereof
CN111757757A (zh) 2017-12-21 2020-10-09 梅尔莎纳医疗公司 吡咯并苯并二氮呯抗体共轭物
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
MX2021005048A (es) 2018-10-31 2021-09-08 Bioatla Inc Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CN114174336B (zh) * 2019-07-15 2024-10-11 英特维特国际股份有限公司 针对人和犬ctla-4的犬源化抗体
AU2020312686B2 (en) 2019-07-15 2026-07-30 Intervet International B.V. Caninized antibodies against canine CTLA-4
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
US12595307B2 (en) 2020-06-11 2026-04-07 Nantbio, Inc. Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072340A2 (en) * 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
WO2006059131A1 (en) * 2004-12-03 2006-06-08 The University Court Of The University Of Aberdeen T-cell modulation
WO2008156621A1 (en) * 2007-06-12 2008-12-24 Ac Immune S.A. Monoclonal anti beta amyloid antibody
WO2009008916A2 (en) * 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6107056A (en) * 1996-02-22 2000-08-22 Oaks; Martin K. SCTLA-4 gene and product
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1274733A1 (en) * 2000-04-12 2003-01-15 Genetics Institute, Inc. Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor
IL154751A0 (en) 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
WO2006029219A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
NZ568016A (en) * 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072340A2 (en) * 2004-01-27 2005-08-11 Compugen Ltd. Novel polynucleotides encoding polypeptides and methods using same
WO2006059131A1 (en) * 2004-12-03 2006-06-08 The University Court Of The University Of Aberdeen T-cell modulation
WO2009008916A2 (en) * 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2008156621A1 (en) * 2007-06-12 2008-12-24 Ac Immune S.A. Monoclonal anti beta amyloid antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OAKS, M. et al. "Cutting Edge: A Soluble Form of CTLA-4 in Patients with Autoimmune Thyroid Disease", J Immunol 2000; 164:5015-5018 *

Also Published As

Publication number Publication date
WO2010097597A1 (en) 2010-09-02
CN102421482A (zh) 2012-04-18
AU2010217453A1 (en) 2011-10-20
US20120107320A1 (en) 2012-05-03
JP2012518425A (ja) 2012-08-16
ES2662652T3 (es) 2018-04-09
CA2772648A1 (en) 2010-09-02
JP5864266B2 (ja) 2016-02-17
EP2401035B1 (en) 2017-12-27
US8697845B2 (en) 2014-04-15
EP2401035A1 (en) 2012-01-04
GB0903325D0 (en) 2009-04-08
CN102421482B (zh) 2016-02-24

Similar Documents

Publication Publication Date Title
EP2401035B1 (en) Antibodies specifically directed to the soluble form of ctla-4
TWI754800B (zh) 新型抗ox40/pd-l1雙特異性抗體分子、新型抗vegf/gitr雙特異性抗體分子及其用途
TWI793129B (zh) 細胞毒性t淋巴球相關蛋白4 (ctla-4) 之新穎單株抗體
TWI823895B (zh) 抗b7-h4抗體、其抗原結合片段及其醫藥用途
JP7198761B2 (ja) 抗ｉｃｏｓアゴニスト抗体およびそれらの使用
US20150218279A1 (en) Binding molecules to the human ox40 receptor
KR20200080304A (ko) Cd137에 결합하는 단일 도메인 항체
JP2018520650A (ja) 新規のポリペプチド
JP2020515235A (ja) プログラム細胞死（ｐｄ−１）に対するシングルドメイン抗体
TWI752952B (zh) 投與結合至cd33及cd3之雙特異性建構體來用於治療骨髓樣白血病之方法中
WO2019184909A1 (zh) 新型抗体分子、其制备方法及其用途
CN117964759A (zh) 调节由细胞表达的生物活性的抗体
JP2021513848A (ja) Ｌａｇ３に結合する治療用分子
WO2019137397A1 (zh) Pd-l1抗体、其抗原结合片段及医药用途
CN111655286A (zh) 作为免疫调节剂的cd96结合剂
CA3068932A1 (en) Bispecific anti pd1-anti tim3 antibodies
WO2023045370A1 (zh) 靶向tigit的单克隆抗体
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
CN121335922A (zh) 抗pd-1/ctla-4/vegf抗体及其用途
WO2024193668A1 (zh) 抗ctla-4/抗tigit双特异性抗体及其应用
HK40012331B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
EA042725B1 (ru) Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 26 FEB 2015 TO 26 - 553 - OCT 2015 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 26 OCT 2015 .

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired